Floatz logo

110 assets in Liver Cancer

Therapeutic assets addressing Liver Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Adriamycin
Liver Cancer
Shanghai Zhongshan HospitalP4BB (68)
Oxaliplatin
Liver Cancer
Sun Yat-sen UniversityP3BB (66)
Gardasil 9 Vaccine
Liver Cancer
Eunice DubeP4BB (65)
Hepatitis B Virus Vaccine
Liver Cancer
Eunice DubeP4BB (65)
Idarubicin
Liver Cancer
Second Affiliated Hospital of Guangzhou Medical UniversityP3BB (65)
Jnj-54135419
Liver Cancer
The Second Affiliated Hospital of Chongqing Medical UniversityP4BB (65)
Sufentanyl
Liver Cancer
The Second Affiliated Hospital of Chongqing Medical UniversityP4BB (65)
Tranexamic Acid
Liver Cancer
Konkuk University Medical CenterP4BB (65)
Cis-Diamminedichloroplatinum Ii
Liver Cancer
Sun Yat-sen UniversityP3BB (64)
Iodized Ethyl Esters Of Poppyseed Fatty Acids
Liver Cancer
Sun Yat-sen UniversityP4BB (64)
Fluorouracilum
Liver Cancer
Sun Yat-sen UniversityP3B (63)
Irinotecan
Liver Cancer
Biotheus Inc.P4B (63)
Atezolizumab
Liver Cancer
Niek WijnenP4B (62)
Carboplatin
Liver Cancer
IRCCS Azienda Ospedaliero-Universitaria di BolognaP3B (62)
Capecitabine
Liver Cancer
Niek WijnenP3B (60)
Epirubicin
Liver Cancer
Tang-Du HospitalP2B (60)
Nivolumab
Liver Cancer
M.D. Anderson Cancer CenterP3B (60)
Durvalumab
Liver Cancer
Amit MahipalP2B (56)
Propofol
Liver Cancer
Kaohsiung Medical University Chung-Ho Memorial HospitalP4B (56)
Sevoflurane
Liver Cancer
Kaohsiung Medical University Chung-Ho Memorial HospitalP4B (56)
Sofosbuvir
Liver Cancer
M.D. Anderson Cancer CenterP4B (56)
Velpatasvir
Liver Cancer
M.D. Anderson Cancer CenterP4B (56)
Cyclophosphamide
Liver Cancer
Shanghai Zhongshan HospitalP2CCC (55)
Lenvatinib
Liver Cancer
Lion TCR Pte. Ltd.P2CCC (55)
Pembrolizumab
Liver Cancer
Essen BiotechP2CCC (55)
Ribavirin
Liver Cancer
M.D. Anderson Cancer CenterP4CCC (55)
Docetaxel
Liver Cancer
Shanghai Zhongshan HospitalP2CCC (54)
Ipilimumab
Liver Cancer
Second Affiliated Hospital of Guangzhou Medical UniversityP2CCC (54)
Tislelizumab
Liver Cancer
IRCCS Azienda Ospedaliero-Universitaria di BolognaP2CCC (54)
Angiotensin Ii
Liver Cancer
Niek WijnenP2CCC (53)
Donafenib
Liver Cancer
Sun Yat-sen UniversityP2CCC (53)
Liocyx-M
Liver Cancer
Lion TCR Pte. Ltd.P2CCC (53)
Pucotenlimab
Liver Cancer
Sun Yat-sen UniversityP2CCC (53)
Regorafenib
Liver Cancer
Instituto do Cancer do Estado de São PauloP2CCC (53)
Rivoceranib
Liver Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolP2CCC (53)
Ferric Cation
Liver Cancer
Jon UnossonP3CCC (52)
Voxilaprevir
Liver Cancer
M.D. Anderson Cancer CenterP4CCC (51)
[18f]f-resca-rt4
Liver Cancer
RenJi HospitalP2/3CCC (50)
[18F]F-RESCA-T4
Liver Cancer
RenJi HospitalP2/3CCC (50)
[68ga]ga-nota-rt4
Liver Cancer
RenJi HospitalP2/3CCC (50)
[68ga]ga-nota-t4
Liver Cancer
RenJi HospitalP2/3CCC (50)
TIL
Liver Cancer
Shanghai Juncell TherapeuticsP1CCC (50)
Amsulostat
Liver Cancer
University of RochesterP1/2CCC (48)
Cabozantinib
Liver Cancer
M.D. Anderson Cancer CenterP2CCC (48)
Domvanalimab
Liver Cancer
University of Texas Southwestern Medical CenterP2CCC (48)
Eb-G3B7-Nk Dual-Target Car-Nk Cells
Liver Cancer
Beijing BiotechP1/2CCC (48)
et140203 t cells
Liver Cancer
Eureka Therapeutics Inc.P1/2CCC (48)
Riluzole
Liver Cancer
University of California, IrvineP2CCC (48)
Vipivotide Tetraxetan
Liver Cancer
Melissa LumishP2CCC (48)
Zanzalintinib
Liver Cancer
Amit MahipalP2CCC (48)
Showing 1 to 50 of 110 assets
PreviousPage 1 of 3Next